In combination with Herceptin, small molecules capable of targeted downregulation of ADAM-15 expression, such as those stabilizing the promoter G4, have the potential for synergism and a marked improvement on the lives of thousands of breast cancer patients a year. The gene discussed is ADAM15; the disease is breast cancer.